Curare alkaloids from Matis Dart Poison: Comparison with d-tubocurarine in interactions with nicotinic, 5-HT3 serotonin and GABAA receptors

Several novel bisbenzylisoquinoline alkaloids (BBIQAs) have recently been isolated from a Matis tribe arrow poison and shown by two-electrode voltage-clamp to inhibit mouse muscle nicotinic acetylcholine receptors (nAChR). Here, using radioligand assay with Aplysia californica AChBP and radioiodinated α-bungarotoxin ([125I]-αBgt), we show that BBIQA1, BBIQA2, and d-tubocurarine (d-TC) have similar affinities to nAChR orthosteric site. However, a competition with [125I]-αBgt for binding to the Torpedo californica muscle-type nAChR revealed that BBIQAs1, 2, and 3 are less potent (IC50s = 26.3, 8.75, and 17.0 μM) than d-TC (IC50 = 0.39 μM), while with α7 nAChR in GH4C1 cells, BBIQA1 was less potent that d-TC (IC50s = 162 μM and 7.77 μM, respectively), but BBIQA2 was similar (IC50 = 5.52 μM). In inhibiting the Ca2+ responses induced by acetylcholine in Neuro2a cells expressing the mouse adult α1β1εδ nAChR or human α7 nAChR, BBIQAs1 and 2 had similar potencies to d-TC (IC50s in the range 0.75–3.08 μM). Our data suggest that BBIQA1 and BBIQA2 can inhibit adult muscle α1β1εδ nAChR by both competitive and noncompetitive mechanisms. Further experiments on neuronal α3β2, α4β2, and α9α10 nAChRs, expressed in Xenopus laevis oocytes, showed that similar potencies for BBIQAs1, 2, and d-TC. With α3β2γ2 GABAAR currents were almost completely inhibited by d-TC at a high (100 μM) concentration, but BBIQAs1 and 2 were less potent (only 40–50% inhibition), whereas in competition with Alexa Fluor 546-α-cobratoxin for binding to α1β3γ2 GABAAR in Neuro2a cells, d-TC and these analogs had comparable affinities. Especially interesting effects of BBIQAs1 and 2 in comparison with d-TC were observed for 5-HT3AR: BBIQA1 and BBIQA2 were 5- and 87-fold less potent than d-TC (IC50 = 22.63 nM). Thus, our results reveal that these BBIQAs differ from d-TC in their potencies towards certain Cys-loop receptors, and we suggest that understanding the reasons behind this might be useful for future drug design.

[1]  D. Servent,et al.  α9‐containing nicotinic acetylcholine receptors and the modulation of pain , 2018, British journal of pharmacology.

[2]  M. Zoli,et al.  Neuronal and Extraneuronal Nicotinic Acetylcholine Receptors , 2018, Current neuropharmacology.

[3]  D. Bertrand,et al.  The wonderland of neuronal nicotinic acetylcholine receptors , 2017, Biochemical pharmacology.

[4]  L. Foucault-Fruchard,et al.  Therapeutic potential of α7 nicotinic receptor agonists to regulate neuroinflammation in neurodegenerative diseases , 2017, Neural regeneration research.

[5]  M. Hollmann,et al.  Calcium imaging with genetically encoded sensor Case12: Facile analysis of α7/α9 nAChR mutants , 2017, PloS one.

[6]  R. Weiss,et al.  Nicotinic alpha 7 receptor expression and modulation of the lung epithelial response to lipopolysaccharide , 2017, PloS one.

[7]  M. Serebryakova,et al.  Peptides from puff adder Bitis arietans venom, novel inhibitors of nicotinic acetylcholine receptors. , 2016, Toxicon : official journal of the International Society on Toxinology.

[8]  C. L. Morales-Pérez,et al.  X-ray structure of the human alpha 4 beta 2 nicotinic receptor. , 2016 .

[9]  Paul J. Groot-Kormelink,et al.  High Throughput Random Mutagenesis and Single Molecule Real Time Sequencing of the Muscle Nicotinic Acetylcholine Receptor , 2016, PloS one.

[10]  L. Aguayo,et al.  Structure and Pharmacologic Modulation of Inhibitory Glycine Receptors , 2016, Molecular Pharmacology.

[11]  C. L. Morales-Pérez,et al.  X-ray structure of the human α4β2 nicotinic receptor , 2016, Nature.

[12]  R. Bussmann,et al.  Curare Alkaloids: Constituents of a Matis Dart Poison. , 2015, Journal of natural products.

[13]  N. Millar,et al.  The influence of allosteric modulators and transmembrane mutations on desensitisation and activation of α7 nicotinic acetylcholine receptors , 2015, Neuropharmacology.

[14]  S. Sine,et al.  Stoichiometry for α-bungarotoxin block of α7 acetylcholine receptors , 2015, Nature Communications.

[15]  H. Xu,et al.  Ion channels gated by acetylcholine and serotonin: structures, biology, and drug discovery , 2015, Acta Pharmacologica Sinica.

[16]  W. Sieghart,et al.  Neurotoxins from Snake Venoms and α-Conotoxin ImI Inhibit Functionally Active Ionotropic γ-Aminobutyric Acid (GABA) Receptors* , 2015, The Journal of Biological Chemistry.

[17]  D. Bertrand,et al.  Molecular blueprint of allosteric binding sites in a homologue of the agonist-binding domain of the α7 nicotinic acetylcholine receptor , 2015, Proceedings of the National Academy of Sciences.

[18]  J. Yakel,et al.  Nicotinic ACh receptors as therapeutic targets in CNS disorders. , 2015, Trends in pharmacological sciences.

[19]  I. Vermaak,et al.  From arrow poison to herbal medicine--the ethnobotanical, phytochemical and pharmacological significance of Cissampelos (Menispermaceae). , 2014, Journal of ethnopharmacology.

[20]  T. Tomizaki,et al.  X-ray structure of the mouse serotonin 5-HT3 receptor , 2014, Nature.

[21]  E. Vizi,et al.  Mode of action of the positive modulator PNU-120596 on α7 nicotinic acetylcholine receptors , 2014, Neuropharmacology.

[22]  Christoph Methfessel,et al.  Marine Natural Products Acting on the Acetylcholine-Binding Protein and Nicotinic Receptors: From Computer Modeling to Binding Studies and Electrophysiology , 2014, Marine drugs.

[23]  C. Ulens,et al.  Structural insights into Cys-loop receptor function and ligand recognition. , 2013, Biochemical pharmacology.

[24]  D. Craik,et al.  Isolation and characterization of α-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors. , 2013, Biochemical pharmacology.

[25]  Lin Chen,et al.  Complex between α-bungarotoxin and an α7 nicotinic receptor ligand-binding domain chimaera. , 2013, The Biochemical journal.

[26]  E. Sher,et al.  Contrasting Properties of α7-Selective Orthosteric and Allosteric Agonists Examined on Native Nicotinic Acetylcholine Receptors , 2013, PloS one.

[27]  K. Kawashima,et al.  Critical roles of acetylcholine and the muscarinic and nicotinic acetylcholine receptors in the regulation of immune function. , 2012, Life sciences.

[28]  D. Bertrand,et al.  Pentameric ligand-gated ion channel ELIC is activated by GABA and modulated by benzodiazepines , 2012, Proceedings of the National Academy of Sciences.

[29]  Antoine Taly,et al.  Ligand-gated ion channels: new insights into neurological disorders and ligand recognition. , 2012, Chemical reviews.

[30]  S. Sine,et al.  End-plate acetylcholine receptor: structure, mechanism, pharmacology, and disease. , 2012, Physiological reviews.

[31]  C. Lien.  Development and potential clinical impairment of ultra-short-acting neuromuscular blocking agents. , 2011, British journal of anaesthesia.

[32]  R. Papke,et al.  Positive allosteric modulators as an approach to nicotinic acetylcholine receptor-targeted therapeutics: advantages and limitations. , 2011, Biochemical pharmacology.

[33]  A. Smit,et al.  A Structural and Mutagenic Blueprint for Molecular Recognition of Strychnine and d-Tubocurarine by Different Cys-Loop Receptors , 2011, PLoS biology.

[34]  D. Kleinfeld,et al.  Characterizing Ligand-Gated Ion Channel Receptors with Genetically Encoded Ca++ Sensors , 2011, PloS one.

[35]  P. Rorsman,et al.  γ-Aminobutyric Acid (GABA) Is an Autocrine Excitatory Transmitter in Human Pancreatic β-Cells , 2010, Diabetes.

[36]  Satyavani Vemparala,et al.  Computational studies on the interactions of inhalational anesthetics with proteins. , 2010, Accounts of chemical research.

[37]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[38]  L. Eriksson,et al.  Pharmacological Characteristics of the Inhibition of Nondepolarizing Neuromuscular Blocking Agents at Human Adult Muscle Nicotinic Acetylcholine Receptor , 2009, Anesthesiology.

[39]  K. Ingkaninan,et al.  Triclisia sacleuxii (Pierre) Diels (Menispermaceae), a potential source of acetylcholinesterase inhibitors , 2009 .

[40]  G. Young,et al.  Agonist activation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site , 2008, Proceedings of the National Academy of Sciences.

[41]  G. Young,et al.  Potentiation of α7 nicotinic acetylcholine receptors via an allosteric transmembrane site , 2008, Proceedings of the National Academy of Sciences.

[42]  S. Sine,et al.  The Interface between Extracellular and Transmembrane Domains of Homomeric Cys-Loop Receptors Governs Open-Channel Lifetime and Rate of Desensitization , 2008, The Journal of Neuroscience.

[43]  G. Terstappen,et al.  Functional properties of alpha7 nicotinic acetylcholine receptors co-expressed with RIC-3 in a stable recombinant CHO-K1 cell line. , 2008, Assay and drug development technologies.

[44]  D. Bertrand,et al.  Allosteric modulation of nicotinic acetylcholine receptors. , 2007, Biochemical Pharmacology.

[45]  A. J. Thompson,et al.  The 5-HT3 receptor as a therapeutic target , 2007, Expert opinion on therapeutic targets.

[46]  J. Kew,et al.  Differential coupling of α7 and non‐α7 nicotinic acetylcholine receptors to calcium‐induced calcium release and voltage‐operated calcium channels in PC12 cells , 2007, Journal of neurochemistry.

[47]  B. Hester,et al.  The role of loop F residues in determining differential d-tubocurarine potencies in mouse and human 5-hydroxytryptamine 3A receptors. , 2007, Biochemistry.

[48]  O. Larsson,et al.  Distinct Pharmacologic Properties of Neuromuscular Blocking Agents on Human Neuronal Nicotinic Acetylcholine Receptors: A Possible Explanation for the Train-of-four Fade , 2006, Anesthesiology.

[49]  W. Bowman.  Neuromuscular block , 2006, British journal of pharmacology.

[50]  C. Kindler,et al.  Antiemetics of the 5-Hydroxytryptamine 3A Antagonist Class Inhibit Muscle Nicotinic Acetylcholine Receptors , 2005, Anesthesia and analgesia.

[51]  D. Bertrand,et al.  A Novel Positive Allosteric Modulator of the α7 Neuronal Nicotinic Acetylcholine Receptor: In Vitro and In Vivo Characterization , 2005, The Journal of Neuroscience.

[52]  Conrad C. Huang,et al.  UCSF Chimera—A visualization system for exploratory research and analysis , 2004, J. Comput. Chem..

[53]  N. Horseman,et al.  Serotonin regulates mammary gland development via an autocrine-paracrine loop. , 2004, Developmental cell.

[54]  S. Sine,et al.  Curariform Antagonists Bind in Different Orientations to the Nicotinic Receptor Ligand Binding Domain* , 2003, Journal of Biological Chemistry.

[55]  E. Vizi,et al.  Synthesis and structure-activity relationships of neuromuscular blocking agents. , 2002, Current medicinal chemistry.

[56]  G. Meakin.  Recent advances in myorelaxant therapy , 2001, Paediatric anaesthesia.

[57]  T. Sixma,et al.  Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors , 2001, Nature.

[58]  V. Wotring,et al.  The inhibitory effects of nicotinic antagonists on currents elicited by GABA in rat hippocampal neurons , 1995, Neuroscience.

[59]  W. Bowman,et al.  Structure: action Relationships Among Some Desacetoxy Analogues of Pancuronium and Vecuronium in the Anesthetized Cat , 1988, Anesthesiology.

[60]  J. W. Karpen,et al.  Acetylcholine receptor inhibition by d-tubocurarine involves both a competitive and a noncompetitive binding site as determined by stopped-flow measurements of receptor-controlled ion flux in membrane vesicles. , 1986, Biochemistry.

[61]  R. Kitz,et al.  Does clinical anesthesia need new neuromuscular blocking agents? , 1975, Anesthesiology.

[62]  J. Dutcher,et al.  CURARE ALKALOIDS FROM CHONDODENDRON TOMENTOSUM , 1943, Science.

[63]  M. Chebib,et al.  GABAA Receptors and the Diversity in their Structure and Pharmacology. , 2017, Advances in pharmacology.

[64]  J. A. Dani,et al.  Neuronal Nicotinic Acetylcholine Receptor Structure and Function and Response to Nicotine. , 2015, International review of neurobiology.

[65]  K. Ingkaninan,et al.  Triclisia sacleuxii (Pierre) Diels (Menispermaceae), a potential source of acetylcholinesterase inhibitors. , 2009, The Journal of pharmacy and pharmacology.

[66]  Carisoprodol Soma,et al.  [Muscle relaxants]. , 1980, Klinische Anasthesiologie und Intensivtherapie.